Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics


Verrica Pharmaceuticals Inc. (VRCA)

Today's Latest Price: $10.30 USD

0.14 (1.38%)

Updated Jul 2 4:00pm

Add VRCA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

VRCA Daily Price Range
VRCA 52-Week Price Range

VRCA Stock Price Chart Technical Analysis Charts


VRCA Price/Volume Stats

Current price $10.30 52-week high $18.67
Prev. close $10.16 52-week low $6.79
Day low $10.07 Volume 111,091
Day high $10.72 Avg. volume 67,355
50-day MA $11.82 Dividend yield N/A
200-day MA $13.15 Market Cap 265.88M

Verrica Pharmaceuticals Inc. (VRCA) Company Bio


Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.


VRCA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

VRCA Latest Social Stream


Loading social stream, please wait...

View Full VRCA Social Stream

Latest VRCA News From Around the Web

Below are the latest news stories about Verrica Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRCA as an investment opportunity.

VRCA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA). Investors who purchased Verrica securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/vrca.

Yahoo | July 2, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

Yahoo | July 2, 2020

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc. Investors (VRCA)

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 29, 2020, Verrica disclosed receipt of a letter from the U.S. Food and Drug Administration ("FDA") regarding the Company's New Drug Application

Business Wire | June 30, 2020

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Verrica Pharmaceuticals Inc. on Behalf of Investors

Business Wire | June 30, 2020

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors

Yahoo | June 30, 2020

Read More 'VRCA' Stories Here

VRCA Price Returns

1-mo -17.86%
3-mo -4.36%
6-mo -30.83%
1-year -7.29%
3-year N/A
5-year N/A
YTD -35.18%
2019 94.97%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7482 seconds.